Fig. 3From: Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialEQ-5D-5L VAS. a – LS mean change from baseline up to 36 months. b – Percentage of patients reporting clinically meaningful improvements up to 36 months (ITT population)Back to article page